Skip to main content
SpringerLink
Log in

Fruquintinib in metastatic colorectal cancer: "acceptable" safety profile

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients. The trial was co-funded by Eli Lilly and Company, USA, and Hutchison MediPharma, China.

  2. vascular endothelial growth factor receptor

Reference

  • Li J, et al. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. Advances in Therapy : 8 Sep 2020. Available from: URL: https://doi.org/10.1007/s12325-020-01477-w

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fruquintinib in metastatic colorectal cancer: "acceptable" safety profile. Reactions Weekly 1823, 6 (2020). https://doi.org/10.1007/s40278-020-83634-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-83634-x

Search

Navigation